首页> 外文期刊>Drug Design, Development and Therapy >Improved corneal bioavailability of ofloxacin: biodegradable microsphere-loaded ion-activated in situ gel delivery system
【24h】

Improved corneal bioavailability of ofloxacin: biodegradable microsphere-loaded ion-activated in situ gel delivery system

机译:氧氟沙星改善角膜的生物利用度:可生物降解的微球负载离子活化原位凝胶递送系统

获取原文
       

摘要

Abstract: The aim of the study was to improve corneal penetration and bioavailability of ofloxacin (OFX) eye preparations. OFX was incorporated in poly (lactide-co-glycolide) as biodegradable microspheres using oil in oil emulsion solvent evaporation technique. The prepared OFX microspheres were then incorporated in Gelrite? in situ gel preparation. In addition, OFX Gelrite-based in situ gel formulations were prepared. OFX formulations were characterized for gelling capacity, viscosity, and rheological properties. Release studies for OFX microspheres, OFX in situ gel, and OFX-loaded microspheres in situ gel formulations were carried out to investigate release characteristics of the drug. The prepared OFX formulations were then investigated in vivo compared with commercially available OFX eyedrops. Results showed that the optimum Gelrite concentration was at 0.4%–0.7% w/v; the prepared formulations were viscous liquid transformed into a pourable gel immediately after the addition of simulated tear fluid with a gelling factor of 27–35. Incorporation of OFX-loaded microspheres in Gelrite solution (0.4% w/v) significantly altered the release profiles of OFX-loaded microspheres in situ gel formula compared with the corresponding OFX gels and OFX microspheres. In vivo results in rabbits showed that OFX-loaded microspheres in situ gel formula improved the relative bioavailability by 11.7-fold compared with the commercially available OFX eyedrops. In addition, the longer duration of action of OFX-loaded microspheres in situ gel formula preparations is thought to avoid frequent instillations, which improves patient tolerability and compliance.
机译:摘要:该研究的目的是改善氧氟沙星(OFX)眼用制剂的角膜渗透性和生物利用度。使用油包油乳液溶剂蒸发技术将OFX作为可生物降解的微球掺入聚丙交酯-乙交酯共聚物中。然后将制得的OFX微球掺入Gelrite?原位凝胶制备。另外,制备了基于OFX Gelrite的原位凝胶制剂。对OFX配方的胶凝能力,粘度和流变性进行了表征。对OFX微球,OFX原位凝胶和装有OFX的微球原位凝胶制剂进行了释放研究,以研究药物的释放特性。然后,与市售的OFX滴眼剂进行体内研究,比较制备的OFX制剂。结果表明,最佳的Gelrite浓度为0.4%–0.7%w / v;在添加模拟泪液后,立即将制备的制剂通过粘性因子27-35的粘性液体转化为可倾倒的凝胶。与相应的OFX凝胶和OFX微球相比,在Gelrite溶液(0.4%w / v)中掺入OFX的微球显着改变了原位凝胶配方中的OFX的微球的释放曲线。兔体内实验结果表明,与市售的OFX滴眼剂相比,载有OFX的微球原位凝胶配方将相对生物利用度提高了11.7倍。另外,OFX负载的微球原位凝胶配方制剂的作用时间更长,可以避免频繁滴注,从而提高了患者的耐受性和依从性。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号